детиострый лимфобластный лейкозминимальная резидуальная болезньпроточная цитофлюометриярецидивыchildrenacute lymphoblastic leukemiaminimal residual diseaseflow cytofluorometryrelapses1.Möricke A., Zimmermann M., Reiter A., Henze G., Schrauder A., Gadner H., Ludwig W.D., et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2010; 24(2): 265-84.2.Campana D. Monitoring minimal residual disease in acute leukemia: expectations, possibilities and initial clinical results. Int J Clin Lab Res. 1994; 24(3): 132-8.3.Campana D., Pui C.H. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood. 1995; 85(6): 1416-34.4.Campana D. Determination of minimal residual disease in leukemia patients. Br J Haematol. 2003; 121(6): 823-38.5.Coustan-Smith E., Sancho J., Hancock M.L., Boyett J.M., Behm F.G., Raimondi S.C. et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood. 2000; 96(8): 2691-6.6.Denys B., van der Sluijs-Gelling A.J., Homburg C., van der Schoot C.E., de Haas V., Philippé J. et al. Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia. 2013; 27(3): 635-41.7.Brüggemann M., Raff T., Kneba M. Has MRD monitoring superseded other prognostic factors in adult ALL? Blood. 2012; 120(23): 4470-81.8.van der Velden V.H., Boeckx N., van Wering E.R., van Dongen J.J. Detection of minimal residual disease in acute leukemia. J Biol Regul Homeost Agents. 2004; 18(2): 146-54.9.van Dongen J.J., Macintyre E.A., Gabert J.A., Delabesse E., Rossi V., Saglio G. et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia. 1999; 13(12): 1901-28.10.Dworzak M.N., Panzer-Grümaer E.R. Flow cytometric detection of minimal residual disease in acute lymphoblastic leukemia. Leuk Lymphoma. 2003; 44(9): 1445-55.11.Flohr T., Schrauder A., Cazzaniga G., Panzer-Grümayer R., van der Velden V., Fischer S. et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia. 2008; 22(4): 771-82.12.van der Velden V.H., Cazzaniga G., Schrauder A., Hancock J., Bader P., Panzer-Grumayer E.R. et al. European Study Group on MRD detection in ALL (ESG-MRD-ALL). Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007; 21(4): 604-11.13.van Dongen J.J., Lhermitte L., Böttcher S., Almeida J., van der Velden V.H., Flores-Montero J. et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012; 26(9): 1908-75.14.Neale G.A., Coustan-Smith E., Stow P., Pan Q., Chen X., Pui C.H. et al. Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia. 2004; 18(5): 934-8.15.Basso G., Buldini B., De Zen L., Orfao A. New methodologic approaches for immunophenotyping acute leukemias. Haematologica. 2001; 86(7): 675-92.16.Borowitz M.J., Devidas M., Hunger S.P., Bowman W.P., Carroll A.J., Carroll W.L. et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood. 2008; 111(12): 5477-85.17.Brüggemann M., Schrauder A., Raff T., Pfeifer H., Dworzak M., Ottmann O.G. et al. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia. 2010; 24(3): 521-35.18.Rabin K.R., Gramatges M.M., Borowitz M.J., Palla S.L., Shi X., Margolin J.F. et al. Absolute lymphocyte counts refine minimal residual disease-based risk stratification in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2012; 59(3): 468-74.19.Basso G., Veltroni M., Valsecchi M.G., Dworzak M.N., Ratei R., Silvestri D. et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J Clin Oncol. 2009; 27(31): 5168-74.20.Brüggemann M., Raff T., Flohr T., Gökbuget N., Nakao M., Droese J. et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood. 2006; 107(3): 1116-23.21.Panzer-Grümayer E.R., Schneider M., Panzer S., Fasching K., Gadner H. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood. 2000; 95(3): 790-4.22.Stow P., Key L., Chen X., Pan Q., Neale G.A., Coustan-Smith E. et al. Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood. 2010; 115(23): 4657-63.23.zur Stadt U., Harms D.O., Schlüter S., Jorch N., Spaar H.J., Nürnberger W. et al. Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase. Klin Padiatr. 2000; 212(4): 169-73.24.Conter V., Bartram C.R., Valsecchi M.G., Schrauder A., Panzer-Grümayer R., Möricke A. et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010; 115(16): 3206-14.25.Roberts W.M., Estrov Z., Ouspenskaia M.V., Johnston D.A., McClain K.L., Zipf T.F. Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. N Engl J Med. 1997; 336(5): 317-23.26.Cazzaniga G., Gaipa G., Rossi V., Biondi A. Minimal residual disease as a surrogate marker for risk assignment to ALL patients. Rev Clin Exp Hematol. 2003; 7(3): 292-323.27.Davies S.M., Borowitz M.J., Rosner G.L., Ritz K., Devidas M., Winick N. et al. Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2008; 111(6): 2984-90.28.Brüggemann M., Gökbuget N., Kneba M. Acute lymphoblastic leukemia: monitoring minimal residual disease as a therapeutic principle. Semin Oncol. 2012; 39(1): 47-57.29.Kwok C.S., Kham S.K., Ariffin H., Lin H.P., Quah T.C., Yeoh A.E. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblactic leukemia (ALL). Pediatr Blood Cancer. 2006; 47(3): 299-304.30.Davies S.M., Borowitz M.J., Rosner G.L., Ritz K., Devidas M., Winick N. et al. Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2008; 111(6): 2984-90.31.Мигаль Н.В., Савва Н.Н., Белевцев М.В., Савицкий В.П., Петина О.В., Быданов О.И. и др. Оценка эффективности полихимиотерапии путем определения минимальной резидуальной болезни у детей с острым лимфобластным лейкозом. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2009; 8(1): 33-8.32.Савва Н.Н., Красько О.В., Белевцев М.В., Савицкий В.П., Мигаль Н.В., Алейникова О.В. Прогностическое значение минимальной остаточной болезни для безрецидивной выживаемости детей с острым лимфобластным лейкозом на протоколе ОЛЛ-МБ-2002 (однофакторный и многофакторный анализ). Онкогематология. 2009; 2: 17-21.33.Карачунский А.И., Румянцева Ю.В., Румянцев А.Г. Эволюция лечения острого лимфобластного лейкоза у детей: критическое использование мирового опыта в России. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2011; 10(2): 15-31.34.Conter V., Bartram C.R., Valsecchi M.G., Schrauder A., Panzer-Grümayer R., Möricke A. et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010; 115(16): 3206-14.35.Chen I.M., Harvey R.C., Mullighan C.G., Gastier-Foster J., Wharton W., Kang H. et al. Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study. Blood. 2012; 119(15): 3512-22.36.Kang H., Chen I.M., Wilson C.S., Bedrick E.J., Harvey R.C., Atlas S.R. et al. Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia. Blood. 2010; 115(7): 1394-405.